Nov. 21 - A venture funding database, Novartis’ gene therapy deal and a four-in-one obesity drug
Novartis wagers more than $1B on gene therapies for the nervous system; Versant startup sets out to make a new type of obesity drug; Amgen picks prolific biotech founder Chang as new top scientist; What might a Trump administration mean for the Biosecure Act?
See the ways Chromium Single Cell innovations deliver superior performance while driving down costs and taking throughput to new heights.
Find out more.
Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into the industry with this database.
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.
RNA is squarely in drug developers’ sights after the clinical success of medicines that block gene expression by disrupting RNA. Explore the latest advancements in research in this Trendline.
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.
Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.
